Latest News for AZN

Authoritative coverage of AZN: earnings, product launches, management updates, regulatory filings, and trusted third‑party analysis to support research and due diligence.

Quick links:Overview•Financial Metrics•Technicals•Returns•Market Cap & EV•Financials

AstraZeneca 'magic' faces rare test after trial failure, share slide

reuters.com•

4 days ago

AstraZeneca 'magic' faces rare test after trial failure, share slide

AstraZeneca's long-time CEO Pascal Soriot has rarely put a foot wrong. The company's shares have more that quadrupled in price during his 14-year tenure, soaring above the wider FTSE 100 index ‌and main British rival GSK.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN

prnewswire.com•

5 days ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN

NEW YORK, July 23, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NYSE: AZN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

AR Asset Management Inc. Sells 4,000 Shares of Astrazeneca Plc $AZN

defenseworld.net•

5 days ago

AR Asset Management Inc. Sells 4,000 Shares of Astrazeneca Plc $AZN

AR Asset Management Inc. decreased its stake in shares of Astrazeneca Plc (NYSE: AZN) by 50.0% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,000 shares of the company's stock after selling 4,000 shares during the period. AR Asset

AstraZeneca Wins EU Approval for Breast-Cancer Drug as U.S. Review Continues

wsj.com•

5 days ago

AstraZeneca Wins EU Approval for Breast-Cancer Drug as U.S. Review Continues

The approval opens a big market for camizestrant as U.S. regulators continue to review the company's application there.

AZN Investors Have Opportunity to Join AstraZeneca PLC Fraud Investigation with the Schall Law Firm

gurufocus.com•

6 days ago

AZN Investors Have Opportunity to Join AstraZeneca PLC Fraud Investigation with the Schall Law Firm

[url="]The Schall Law Firm[/url], a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of AstraZeneca

businesswire.com•

6 days ago

AZN Investors Have Opportunity to Join AstraZeneca PLC Fraud Investigation with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)---- $AZN--AZN Investors Have Opportunity to Join AstraZeneca PLC Fraud Investigation with the Schall Law Firm.

Jefferies says September lung data can offset AstraZeneca trial failure

proactiveinvestors.com•

6 days ago

Jefferies says September lung data can offset AstraZeneca trial failure

Jefferies believes detailed data on AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) experimental lung drug tozorakimab could more than compensate investors for the...

proactiveinvestors.co.uk•

6 days ago

Jefferies says September lung data can offset AstraZeneca trial failure

Jefferies believes detailed data on AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) experimental lung drug tozorakimab could more than compensate investors for the recent failure of a separate heart trial. The bank has reiterated its buy rating and 17,500p price target, implying 41% upside from the current 12,380p, and flagged the 8 September presentation at the European Respiratory Society congress as the key catalyst.

Stay Ahead of the Game With Astrazeneca (AZN) Q2 Earnings: Wall Street's Insights on Key Metrics

zacks.com•

6 days ago

Stay Ahead of the Game With Astrazeneca (AZN) Q2 Earnings: Wall Street's Insights on Key Metrics

Evaluate the expected performance of Astrazeneca (AZN) for the quarter ended June 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Biotech's takeover boom may be running out of buyers

proactiveinvestors.co.uk•

6 days ago

Biotech's takeover boom may be running out of buyers

Biotech dealmaking has reached a level this year that has already outstripped the whole of 2025, and RBC Capital Markets thinks the pace is unlikely to hold. Cumulative deal value in the first half of 2026 came to $78 billion, against $42 billion for the entirety of last year, according to the bank's half-year sector review.

Royalty Pharma acquires royalty interest in AstraZeneca's cliramitug for up to $425 million from Neurimmune

globenewswire.com•

6 days ago

Royalty Pharma acquires royalty interest in AstraZeneca's cliramitug for up to $425 million from Neurimmune

NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a portion of Neurimmune's royalty interest in AstraZeneca's cliramitug for up to $425 million, including $125 million upfront.

These major drug stocks rally after Trump's zero tariff announcement

finbold.com•

6 days ago

These major drug stocks rally after Trump's zero tariff announcement

President Donald Trump has announced that all generic drugs imported into the United States would continue to enjoy a zero-percent tariff for another two years, sending major drug stocks up.

Varon Corp expands Ballislife HYDRO into Canada through Shoot 360 partnership

proactiveinvestors.com•

6 days ago

Varon Corp expands Ballislife HYDRO into Canada through Shoot 360 partnership

Varon Corp (OTCID:OZSC) announced that Ballislife Drink Inc, its joint venture with Varon USA and Ballislife Inc, has signed a multi-year exclusive deal...

Aftermath Silver begins drilling at Berenguela copper target and Chile's Challacollo project

proactiveinvestors.com•

6 days ago

Aftermath Silver begins drilling at Berenguela copper target and Chile's Challacollo project

Aftermath Silver Ltd (TSX-V:AAG, OTCQX:AAGFF, FRA:FLM1) announced that it has started drilling at the eastern edge of its Berenguela project in Peru to test...

globenewswire.com•

Jul 21, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AstraZeneca PLC- AZN

NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC (“AstraZeneca” or the “Company”) (NYSE: AZN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

4,699 Shares in Astrazeneca Plc $AZN Purchased by Baader Bank Aktiengesellschaft

defenseworld.net•

Jul 21, 2026

4,699 Shares in Astrazeneca Plc $AZN Purchased by Baader Bank Aktiengesellschaft

Baader Bank Aktiengesellschaft acquired a new position in Astrazeneca Plc (NYSE: AZN) in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 4,699 shares of the company's stock, valued at approximately $920,000. Several other large investors have also modified

Andra AP fonden Makes New $46.60 Million Investment in Astrazeneca Plc $AZN

defenseworld.net•

Jul 21, 2026

Andra AP fonden Makes New $46.60 Million Investment in Astrazeneca Plc $AZN

Andra AP fonden bought a new position in shares of Astrazeneca Plc (NYSE: AZN) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 236,302 shares of the company's stock, valued at approximately $46,603,000. Astrazeneca comprises 0.6% of Andra

Social Sentiment

Want to see how the market feels about AZN? View real-time social sentiment analysis from Twitter and StockTwits to gauge crowd psychology and potential price impacts.

View Social Sentiment